Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioArctic ABLTS:0RV2 -1.26%76 PB Ratio is 12.00 as of Jul. 18, 2026, which is 4% below its 10-year median of 12.53. GuruFocus rates LTS:0RV2 with a GF Score™ of 76/100 and a GF Value™ of kr474.38 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,227 Biotechnology companies, BioArctic AB ranks worse than 88.51% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-18), BioArctic AB's share price is kr297.20. BioArctic AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr24.78. Hence, BioArctic AB's PB Ratio of today is 12.00.
The historical rank and industry rank for BioArctic AB's PB Ratio or its related term are showing as below:
LTS:0RV2'
s PB Ratio Range Over the Past 10 Years
Min: 2.95 Med: 12.53 Max: 40.38
Current: 12.12
During the past 11 years, BioArctic AB's highest PB Ratio was 40.38. The lowest was 2.95. And the median was 12.53.
LTS:0RV2's PB Ratio is ranked worse than 88.51% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs LTS:0RV2: 12.12
During the past 12 months, BioArctic AB's average Book Value Per Share Growth Rate was 13.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 35.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 26.60% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of BioArctic AB was 152.20% per year. The lowest was -8.10% per year. And the median was 8.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioArctic AB PB Ratio Related Terms
BioArctic AB PB Ratio Historical Data
* Premium members only.
The historical data trend for BioArctic AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioArctic AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioArctic AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
BioArctic AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioArctic AB (LTS:0RV2) has a PB Ratio of 12.00 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioArctic AB and its competitors. This is near median its historical median of 12.53. Over the past decade, BioArctic AB's PB Ratio has ranged from 2.95 to 40.38. According to the industry distribution chart, BioArctic AB ranks #1086 out of 1227 companies in the Biotechnology industry, placing it in the top 88.5%.
Is BioArctic AB's PB Ratio too high?
BioArctic AB's current PB Ratio of 12.00 is near median its 10-year median of 12.53. Over the past 10 years, this metric has ranged from a low of 2.95 to a high of 40.38. The Biotechnology industry median PB Ratio is 2.82. BioArctic AB's value of 12.00 is 325.5% above this industry median. Based on the distribution chart, BioArctic AB ranks #1086 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioArctic AB has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #1086 out of 1227 companies for PB Ratio. This places BioArctic AB in the lower half of its industry. The industry median PB Ratio is 2.82. BioArctic AB's value of 12.00 is 325.5% above this benchmark. Historically, BioArctic AB's own PB Ratio has ranged from 2.95 to 40.38 over the past decade. While the company's 10-year median is 12.53 vs. the industry median of 2.82, BioArctic AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioArctic AB's current PB Ratio of 12.00 is 325.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioArctic AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioArctic AB's current PB Ratio is 12.00, which is near median its own 10-year median of 12.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (LTS:0RV2) is currently considered Significantly Undervalued. The stock's GF Value™ is kr474.38, compared to a current price of kr297.20 — trading 37.3% below its estimated fair value. The current PB Ratio is 12.00, which is near median its 10-year median of 12.53 and 325.5% above the Biotechnology industry median of 2.82. BioArctic AB's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current PB Ratio is 12.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (LTS:0RV2) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of kr297.20 is trading 37.3% below its estimated GF Value™ of kr474.38.
GuruFocus considers BioArctic AB to be Significantly Undervalued.
Key valuation signals for LTS:0RV2:
PB Ratio: 12.00 (near median its 10-year median of 12.53)
GF Value™: kr474.38 vs. price of kr297.20 (37.3% below fair value)
Industry Position: 325.5% above the Biotechnology median (#1086 of 1227)
No single metric tells the full story. See the LTS:0RV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
76GF Score
Get the complete analysis for LTS:0RV2
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RV2 has been successfully added to your 
